Hinge Health Reports Strong Q4 & Full Year 2025 Results, Initiates Share Repurchase
HNGE sits 15% above its 52-week low of $30.08 on elevated volume (1.9× avg).
Summary
Hinge Health reported record Q4 and full year 2025 financial results with strong revenue growth, significant profitability improvements, robust free cash flow, and initiated a share repurchase program, alongside positive 2026 guidance.
Key Events · Earnings and Guidance · HNGE
-
Record Q4 and Full Year 2025 Financial Results
Hinge Health reported Q4 2025 revenue of $170.7 million, a 46% increase year-over-year, and full year 2025 revenue of $587.9 million, up 51% from 2024.
-
Significant Profitability Improvement
Non-GAAP income from operations for Q4 2025 surged 124% to $48.0 million, and for the full year 2025, the company achieved non-GAAP income from operations of $119.5 million, a substantial turnaround from a loss in 2024.
-
Strong Free Cash Flow Generation
The company generated $61.5 million in free cash flow in Q4 2025, a 65% increase, and $179.6 million for the full year 2025, representing a 297% increase year-over-year.
-
Share Repurchase Program Activity
Hinge Health repurchased $65.0 million of its Class A common stock during Q4 2025, as part of a $250.0 million program authorized in November 2025.
Analysis · HNGE · Technology
Hinge Health, Inc. announced robust financial results for the fourth quarter and full year 2025, demonstrating significant growth and a strong shift towards profitability. The company reported substantial year-over-year revenue increases and a remarkable improvement in non-GAAP operating income, moving from a loss in 2024 to a significant profit in 2025. The strong free cash flow generation and the execution of a share repurchase program underscore the company's financial health and commitment to shareholder returns. The positive guidance for 2026 suggests continued momentum in revenue growth and expanding margins, reinforcing investor confidence in its digital musculoskeletal care leadership.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.7% of the 1694 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HNGE was trading at $34.65 on NYSE in the Technology sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $30.08 to $62.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.